Your browser doesn't support javascript.
Show: 20 | 50 | 100
Results 1 - 6 de 6
Filter
1.
Ann Oper Res ; : 1-20, 2023 Mar 21.
Article in English | MEDLINE | ID: covidwho-2275481

ABSTRACT

Due to the COVID-19 outbreak, industries have gained a thrust on contactless processing for computing technologies and industrial automation. Cloud of Things (CoT) is one of the emerging computing technologies for such applications. CoT combines the most emerging cloud computing and the Internet of Things. The development in industrial automation made them highly interdependent because the cloud computing works like a backbone in IoT technology. This supports the data storage, analytics, processing, commercial application development, deployment, and security compliances. Now amalgamation of cloud technologies with IoT is making utilities more useful, smart, service-oriented, and secure application for sustainable development of industrial processes. As the pandemic has increased access to computing utilities remotely, cyber-attacks have been increased exponentially. This paper reviews the CoT's contribution to industrial automation and the various security features provided by different tools and applications used for the circular economy. The in-depth analysis of security threats, availability of different features corresponding the security issues in traditional and non-traditional CoT platforms used in industrial automation have been analysed. The security issues and challenges faced by IIoT and AIoT in industrial automation have also been addressed.

2.
Biochim Biophys Acta Mol Basis Dis ; 1869(3): 166634, 2023 03.
Article in English | MEDLINE | ID: covidwho-2228036

ABSTRACT

Coronavirus disease 19 (COVID-19) is caused by a highly contagious RNA virus Severe Acute Respiratory Syndrome coronavirus-2 (SARS-CoV-2), originated in December 2019 in Wuhan, China. Since then, it has become a global public health concern and leads the disease table with the highest mortality rate, highlighting the necessity for a thorough understanding of its biological properties. The intricate interaction between the virus and the host immune system gives rise to diverse implications of COVID-19. RNA viruses are known to hijack the host epigenetic mechanisms of immune cells to regulate antiviral defence. Epigenetics involves processes that alter gene expression without changing the DNA sequence, leading to heritable phenotypic changes. The epigenetic landscape consists of reversible modifications like chromatin remodelling, DNA/RNA methylation, and histone methylation/acetylation that regulates gene expression. The epigenetic machinery contributes to many aspects of SARS-CoV-2 pathogenesis, like global DNA methylation and receptor angiotensin-converting enzyme 2 (ACE2) methylation determines the viral entry inside the host, viral replication, and infection efficiency. Further, it is also reported to epigenetically regulate the expression of different host cytokines affecting antiviral response. The viral proteins of SARS-CoV-2 interact with various host epigenetic enzymes like histone deacetylases (HDACs) and bromodomain-containing proteins to antagonize cellular signalling. The central role of epigenetic factors in SARS-CoV-2 pathogenesis is now exploited as promising biomarkers and therapeutic targets against COVID-19. This review article highlights the ability of SARS-CoV-2 in regulating the host epigenetic landscape during infection leading to immune evasion. It also discusses the ongoing therapeutic approaches to curtail and control the viral outbreak.


Subject(s)
COVID-19 , Humans , COVID-19/genetics , SARS-CoV-2 , Antiviral Agents/therapeutic use , Cytokines , Epigenesis, Genetic
3.
Hum Immunol ; 83(4): 346-355, 2022 Apr.
Article in English | MEDLINE | ID: covidwho-1702841

ABSTRACT

COVID-19 originated in Wuhan city, China, in 2019 erupted a global pandemic that had put down nearly 3 million lives and hampered the socio-economic conditions of all nations. Despite the available treatments, this disease is not being controlled totally and spreading swiftly. The deadly virus commences infection by hACE2 receptor and its co-receptors (DPP4) engagement with the viral spike protein in the lung alveolar epithelial cells, indicating a primary therapeutic target. The current research attempts to design an in-silico Bispecific antibody (BsAb) against viral spike glycoprotein and DPP4 receptors. Regdanvimab and Begelomab were identified to block the D614G mutated spike glycoprotein of SARS-CoV-2 and host DPP4 receptor, respectively. The designed BsAb was modified by using KIH (Knobs into Holes) and CrossMAb techniques to prevent heavy chain and light chain mispairings. Following the modifications, the site-specific molecular docking studies were performed, revealing a relatively higher binding affinity of BsAb with spike glycoprotein and DPP4 co-receptor than control BsAb. Also, for blocking the primary entry receptor, hACE2, an anti-viral peptide was linked to the Fc region of BsAb that blocks the hACE2 receptor by linker cleavage inside the infected host. Thus, the designed BsAb and anti-viral peptide therapy could be a promising triumvirate way to obstruct the viral entry by blocking the receptor engagement.


Subject(s)
COVID-19 , Spike Glycoprotein, Coronavirus , Angiotensin-Converting Enzyme 2 , Antibodies, Monoclonal, Humanized , Antibodies, Neutralizing , Dipeptidyl Peptidase 4/metabolism , Humans , Immunoglobulin G , Molecular Docking Simulation , Protein Binding , SARS-CoV-2 , Spike Glycoprotein, Coronavirus/chemistry , Spike Glycoprotein, Coronavirus/metabolism
4.
Human immunology ; 2022.
Article in English | EuropePMC | ID: covidwho-1615303

ABSTRACT

COVID-19 originated in Wuhan city, China, in 2019 erupted a global pandemic that had put down nearly 3 million lives and hampered the socio-economic conditions of all nations. Despite the available treatments, this disease is not being controlled totally and spreading swiftly. The deadly virus commences infection by hACE2 receptor and its co-receptors (DPP4) engagement with the viral spike protein in the lung alveolar epithelial cells, indicating a primary therapeutic target. The current research attempts to design an in-silico Bispecific antibody (BsAb) against viral spike glycoprotein and DPP4 receptors. Regdanvimab and Begelomab were identified to block the D614G mutated spike glycoprotein of SARS-CoV-2 and host DPP4 receptor, respectively. The designed BsAb was modified by using KIH (Knobs into Holes) and CrossMAb techniques to prevent heavy chain and light chain mispairings. Following the modifications, the site-specific molecular docking studies were performed, revealing a relatively higher binding affinity of BsAb with spike glycoprotein and DPP4 co-receptor than control BsAb. Also, for blocking the primary entry receptor, hACE2, an anti-viral peptide was linked to the Fc region of BsAb that blocks the hACE2 receptor by linker cleavage inside the infected host. Thus, the designed BsAb and anti-viral peptide therapy could be a promising triumvirate way to obstruct the viral entry by blocking the receptor engagement.

5.
Complexity ; 2021, 2021.
Article in English | ProQuest Central | ID: covidwho-1593817

ABSTRACT

Nowadays, the whole world is facing a pandemic situation in the form of coronavirus diseases (COVID-19). In connection with the spread of COVID-19 confirmed cases and deaths, various researchers have analysed the impact of temperature and humidity on the spread of coronavirus. In this paper, a deep transfer learning-based exhaustive analysis is performed by evaluating the influence of different weather factors, including temperature, sunlight hours, and humidity. To perform all the experiments, two data sets are used: one is taken from Kaggle consists of official COVID-19 case reports and another data set is related to weather. Moreover, COVID-19 data are also tested and validated using deep transfer learning models. From the experimental results, it is shown that the temperature, the wind speed, and the sunlight hours make a significant impact on COVID-19 cases and deaths. However, it is shown that the humidity does not affect coronavirus cases significantly. It is concluded that the convolutional neural network performs better than the competitive model.

6.
ACS Appl Bio Mater ; 4(2): 1178-1190, 2021 02 15.
Article in English | MEDLINE | ID: covidwho-1091529

ABSTRACT

Ongoing pandemic coronavirus (COVID-19) has affected over 218 countries and infected 88,512,243 and 1,906,853 deaths reported by Jan. 8, 2021. At present, vaccines are being developed in Europe, Russia, USA, and China, although some of these are in phase III of trials, which are waiting to be available for the general public. The only option available now is by vigorous testing, isolation of the infected cases, and maintaining physical and social distances. Numerous methods are now available or being developed for testing the suspected cases, which may act as carriers of the virus. In this review, efforts have been made to discuss the conventional as well as fast, rapid, and efficient testing methods developed for the diagnosis of 2019-nCoV.Testing methods can be based on the sensing of targets, which include RNA, spike proteins and antibodies such as IgG and IgM. Apart from the development of RNA targeted PCR, antibody and VSV pseudovirus neutralization assay along with several other diagnostic techniques have been developed. Additionally, nanotechnology-based sensors are being developed for the diagnosis of the virus, and these are also discussed.


Subject(s)
Biosensing Techniques/methods , COVID-19/diagnosis , SARS-CoV-2/chemistry , Spike Glycoprotein, Coronavirus/analysis , Animals , Antibodies, Immobilized/immunology , Antibodies, Neutralizing/analysis , Antibodies, Neutralizing/immunology , Antibodies, Viral/immunology , Graphite/chemistry , Humans , Metal Nanoparticles/chemistry , Nanotechnology/methods , SARS-CoV-2/immunology , Spike Glycoprotein, Coronavirus/immunology
SELECTION OF CITATIONS
SEARCH DETAIL